Business opportunities for interested partners
- Licensing deals
- Acquisitions
- Joint R&D projects
- Commercial partnerships
In-licensing
What we are looking for
Almirall is permanently searching and seeking new licensing and M&A opportunities in dermatology, mainly projects which have passed the proof-of-concept in man successfully. Thanks to our expertise in this therapeutic area and a straightforward initial assessment process, we are able to react rapidly and move negotiations forward in a short time.
To review what Almirall is looking for in other therapeutic areas, please visit
What we offer
Almirall's business model is a successful combination of R&D and corporate development where in-licensing will continue to be a key driver of future growth for our company. Our most recent in-licensing deals (eg. Sativex, Sitagliptin, Linaclotide, Silodosin) illustrate Almirall potential of establishing alliances from biotech to Big Pharma companies.
Our experience allows us to provide significant added value to companies who want to partner with a dynamic and growing mid size European company, capable of successfully marketing its assets, and willing to give the right priority to the in-licensed projects.
Our clinical and regulatory teams will offer their experience and expertise to ensure that the most appropriate development is carried out and the project successfully reaches the market.
How we work
Almirall actively looks for business opportunities with a common objective, shared by the entire organisation: to obtain licenses with high added value, forward-looking products and technologies to provide society with innovative drugs that contribute to improving the health and quality of life of human beings. Almirall can assist our partners at clinical development, regulatory process, price setting and marketing level.
Partnering opportunities in dermatology
As the Centre of Excellence in Dermatology link to R&D, Almirall Hermal GmbH in Reinbek stands for outstanding expertise in skin medicine. We are the market leader in Germany and # 8 in Europe with the highest growth rates among the leading dermatological companies.
Our portfolio offers 3 strategic brands- Solaraze (actinic keratosis)
- Vaniqa (hirsutism)
- Balneum (atopic dermatitis, psoriasis, dry skin)
and it is completed by nearly 40 additional brands covering the major dermatological indications.
The Derma Unit is the centrepiece of Almirall's Centre of Excellence in Dermatology and consists of the following functions:- R & D
- Global Marketing & Medical Affairs
- Business Development & Licensing
The pharmaceutical plant in Reinbek is specialised in the production of liquid and semi-solid preparations. The systems are cGMP certified and FDA approved.
As Almirall's Centre of Excellence in Dermatology we have the resources to turn development projects into approved medicines and then to manufacture and successfully market them.
Have we awakened your interest? Your contact person for dermatological opportunities (licensing and M&A) is: Dr. Andreas Beckmann
print 
Start of page